In tumor immunotherapy, programmed death receptor programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors are the main immune checkpoint inhibitors (ICIs) (6, 7). This evidence concerns the gene CTLA4 and neoplasm.